Topical Chlorhexidine 0.2% versus Topical Natamycin 5% for the Treatment of Fungal Keratitis in Nepal: A Randomized Controlled Noninferiority Trial

Simple item page
dc.contributor.authorHoffman, Jeremy J.
dc.contributor.authorYadav, Reena
dc.contributor.authorSanyam, Sandip D.
dc.contributor.authorChaudhary, Pankaj
dc.contributor.authorRoshan, Abhishek
dc.contributor.authorSingh, Sanjay K.
dc.contributor.authorSingh, Sanjay K.
dc.contributor.authorMishra, Sailesh K.
dc.contributor.authorArunga, Simon
dc.contributor.authorHu, Victor H.
dc.contributor.authorMacleod, David
dc.contributor.authorLeck, Astrid
dc.contributor.authorBurton, Matthew J.
dc.date.accessioned2023-03-28T17:48:40Z
dc.date.available2023-03-28T17:48:40Z
dc.date.issued2022
dc.description.abstractTo investigate if topical chlorhexidine 0.2%, which is low cost and easy to formulate, is noninferior to topical natamycin 5% for the treatment of filamentous fungal keratitis. Design: Randomized controlled, single-masked, noninferiority clinical trial. Participants: Adults attending a tertiary-level ophthalmic hospital in Nepal with filamentous fungal infection confirmed on smear or confocal microscopy. Methods: Participants were randomly allocated to receive topical chlorhexidine 0.2% or topical natamycin 5%. Primary analysis (intention-to-treat) was by linear regression, using baseline logarithm of the minimum angle of resolution (logMAR) best spectacle-corrected visual acuity (BSCVA) and treatment arm as prespecified covariates. Mixed fungal-bacterial infections were excluded from the primary analysis but included in secondary analyses and secondary safety-related outcomes. The noninferiority margin was 0.15 logMAR. This trial was registered with ISRCTN, number ISRCTN14332621. Main Outcome Measures: The primary outcome measure was BSCVA at 3 months. Secondary outcome measures included perforation or therapeutic penetrating keratoplasty by 90 days. Results: Between June 3, 2019, and November 9, 2020, 354 eligible participants were enrolled and randomly assigned: 178 to chlorhexidine and 176 to natamycin. Primary outcome data were available for 153 and 151 of the chlorhexidine and natamycin groups, respectively. Of these, mixed bacterial-fungal infections were found in 20 cases (12/153 chlorhexidine, 8/151 natamycin) and excluded from the primary analysis. Therefore, 284 patients were assessed for the primary outcome (141 chlorhexidine, 143 natamycin). We did not find evidence to suggest chlorhexidine was noninferior to natamycin and in fact found strong evidence to suggest that natamycin-treated participants had significantly better 3-month BSCVA than chlorhexidine-treated participants, after adjusting for baseline BSCVA (regression coefficient, 0.30; 95% confidence interval [CI], 0.42 to 0.18; P < 0.001). There were more perforations and emergency corneal grafts in the chlorhexidine arm (24/175, 13.7%) than in the natamycin arm (10/173, 5.8%; P ¼ 0.018, mixed infections included), whereas natamycin-treated cases were less likely to perforate or require an emergency corneal graft, after adjusting for baseline ulcer depth (odds ratio, 0.34; 95% CI, 0.15e0.79; P ¼ 0.013). Conclusions: Treatment with natamycin is associated with significantly better visual acuity, with fewer adverse events, compared with treatment with chlorhexidine. Natamycin remains the preferred first-line monotherapy treatment for filamentous fungal keratitis. Ophthalmology 2022;129:530-541 ª 2021 by the American Academy of Ophthalmology.en_US
dc.identifier.citationHoffman, J. J., Yadav, R., Sanyam, S. D., Chaudhary, P., Roshan, A., Singh, S. K., ... & Burton, M. J. (2022). Topical chlorhexidine 0.2% versus topical natamycin 5% for the treatment of fungal keratitis in Nepal: a randomized controlled noninferiority trial. Ophthalmology, 129(5), 530-541. https://doi.org/10.1016/j.ophtha.2021.12.004en_US
dc.identifier.issnhttps://doi.org/10.1016/j.ophtha.2021.12.004
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8320
dc.language.isoenen_US
dc.publisherOphthalmologyen_US
dc.subjectTopical Chlorhexidineen_US
dc.subjectTopical Natamycinen_US
dc.subjectTreatmenten_US
dc.subjectFungal Keratitisen_US
dc.titleTopical Chlorhexidine 0.2% versus Topical Natamycin 5% for the Treatment of Fungal Keratitis in Nepal: A Randomized Controlled Noninferiority Trialen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Topical Chlorhexidine 0.2% versus Topical.pdf
Size:
729.4 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences